Nalena Review
Appears to have shut downNalena is closed and is not taking new patients. It charged from $149 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Nalena is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $149/mo. No longer offered.
See our top-rated GLP-1 providers →Nalena was a women-focused telehealth seller of compounded GLP-1 medication. It no longer operates. In October 2026 its domain sold only an erectile-dysfunction tablet under Vigo MD, a different operator, with no weight-loss program.
Vetted alternatives to Nalena
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Nalena at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $149/mo
- What it included
- Medication · Consult · Shipping
- Availability
- All 50 states
- FDA status
- No FDA warning letters found
How Nalena scores
Nalena has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something Nalena published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
3.0/10The listed figure is not a comparable monthly price for a named GLP-1 (it may be a membership fee, an insured copay, a per-vial rate or a starting-dose price), so Value is capped rather than scored against other sellers.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
7.5/10No pharmacy is named for its prescriptions. It shows a price before asking for health information. It lists the states it serves.
Accessibility10%
10.0/10Serves all 50 states.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Nalena
Last checked June 2026- Checked the listed price across 2 dose or plan tiers
- Checked state coverage: all 50
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Nalena
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Cancelling Nalena
Taken from the terms Nalena publishes. Terms change, so check the current policy before you subscribe.
- Cancel any time
- Yes
- Minimum commitment
- None
- Refund policy
- Not published by the seller
- Early-termination fee
- None
Medications Nalena listed
Nalena listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
In its favor
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
- The monthly price included the medication, clinician visits and shipping
- Served all 50 states
- We found no FDA warning letters issued to Nalena
Against it
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Nalena is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What Nalena charged
Nalena charged $149/month.
- Compounded semaglutide: $149/month
- Compounded tirzepatide: $149/month
Found, at about $149/month + membership, is the closest like-for-like alternative we review.
What Nalena dispensed
Nalena prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product: the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
Safety and disclosure
Nalena told buyers its price before the medical questionnaire and that it treated patients in all 50 states. We found no FDA warning letters issued to Nalena. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
Nalena is no longer taking new patients, so the choice is among the sellers that are still open.
The Bottom Line
Nalena is closed and is not taking new patients. It charged from $149 a month.
Where Nalena is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to Nalena sets more sellers in the same category beside Nalena on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Nalena review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of June 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.